Abstract
In advanced biliary tract cancer (BTC), combination of cisplatin and gemcitabine is recognized as the standard first-line chemotherapy regimen. Recently, FOLFOX regimen was tested in prospective randomized trial, ABC-06, and revealed to be beneficial as second-line therapy. However, there is no available data regarding the benefit of the treatment beyond first-line in Thai patients. This study aims to evaluate the efficacy of subsequent-line therapy in Advanced BTC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
